top of page

5

2024

Apr.

Our research paper entitled "Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers" was published by Journal for ImmunoTherapy of Cancer.

2

2024

Apr.

Our research paper entitled "ImmunoPET imaging of Trop2 in patients with solid tumours" was published by EMBO Mol Med.

Recent research highlights Trop2 as an adverse prognostic biomarker in multiple solid tumors, correlating its high expression with reduced survival and increased tumor aggressiveness, while targeting Trop2 may impede tumor growth and metastasis.


We have developed two nanobody radiopharmaceuticals targeting human Trop2 with one of the tracers ([68Ga]Ga-NOTA-T4) showing favourable pharmacokinetics and promising diagnostic capabilities in both preclinical studies and a pilot clinical trial.

This work introduces a groundbreaking clinical-grade Trop2 probe in the field of nuclear medicine, marking a significant breakthrough. This innovative tracer holds promise in altering cancer diagnosis and treatment outcomes. With its precision and sensitivity, the Trop2 probe opens new avenues in oncological imaging, enabling earlier detection and more targeted therapies. Its arrival foreshadows a shift towards personalized medicine, equipping clinicians with potent tools to combat cancer effectively.

14

2024

Mar.

Our research paper entitled "ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study" was published by EJNMMI.

CD70 emerges as a promising biomarker for RCC, exhibiting high expression levels within tumors.

Leveraging immunoPET imaging, our research team has developed sdAb tracers targeting CD70, such as [18F]RCCB6, demonstrating potential for precise visualization and monitoring of RCC. Preclinical studies indicate specific uptake of these tracers by CD70-positive tumors. Clinical trial suggests the safety and efficacy of this approach in detecting widespread metastases, including brain metastases, markedly outperforming traditional PET/CT scans. Additionally, our team has prepared tracers like [18F]RB6 by removing His tags from sdAbs, potentially aiding in the detection of primary ccRCC.

Future endeavors of our research team aim to optimize sdAb engineering and assess tracer efficacy in various tumor using advanced imaging techniques.

25

2023

Oct.

In collaboration with Prof. Haojun Chen, we have developed several new integrated probes for FAP theranostics.

19

2023

Oct.

In the short paper, we discussed the essentials of theranostics focusing on antibody theranostics. Together with the opinions from Wolfgang A. Weber et al, we can enrich the contents of theranostics and use theranostic approaches to improve clinical practice.

25

2023

Sept.

The research paper entitled "Site-Specific Modification of Single Domain Antibodies by Enzyme-Immobilized Magnetic Beads" in collaboration with prof. Changfeng Wu‘s group was published by Bioconjugate Chemistry.

Working with Prof. Wu's group, we have devised a new strategy for efficient labelling of single domain antibodies by i
mmobilized-enzymes.

8

2023

Aug.

Our research paper entitled "ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers" was published by EJNMMI.

24

2023

On July 24, 2023, Dr. Wei  became a member of the Editorial Board of the "EJNMMI

Jul.

an internationainterdisciplinary journal that publishes papers in the field of radiopharmaceutical imaging andtherapy, molecular imaging and advanced imaging analyses.

b51f6746_edited.jpg

5

2023

Jul.

Our research paper entitled "ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers" was published by molecular pharmaceutics.

1.jpg

早餐做法
為您提供

5

2023

Jul.

10-11

2023

Mar.

Prof. Dawei Jiang from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and prof. Haojun Chen from the Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University visited our group.

10

2023

Feb.

Our review entitled "Antibody theranostics in precision medicine" was published by Med.

gr1_lrg.jpg

1

2023

Feb.

Our research paper entitled "Development and characterization of nanobody-derived CD47 theranostic pairs in solid tumors" was published by Research.

屏幕截图 2023-02-24 111701.jpg

27

2022

Dec.

Our research paper entitled "Development and comparison of 68Ga/18F/64Cu-labeled nanobody tracers probing Claudin18.2" was published by Molecular Therapy Oncolytics.

Graphical abstract.png

13

2022

Dec.

The website of Weijun Wei's lab is officially launched.

bottom of page